Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 4
1982 21
1983 48
1984 56
1985 53
1986 60
1987 70
1988 138
1989 160
1990 198
1991 180
1992 111
1993 230
1994 258
1995 318
1996 295
1997 305
1998 287
1999 311
2000 330
2001 468
2002 550
2003 575
2004 638
2005 826
2006 1042
2007 1230
2008 1450
2009 1729
2010 1904
2011 2057
2012 2147
2013 2205
2014 2370
2015 2578
2016 2708
2017 2867
2018 2850
2019 1430
2020 35
Text availability
Article attribute
Article type
Publication date

Search Results

30,948 results
Results by year
Filters applied: . Clear all
Page 1
Drug Development of Therapeutic Monoclonal Antibodies.
Mould DR and Meibohm B. BioDrugs 2016 - Review. PMID 27342605
Monoclonal antibodies (MAbs) have become a substantial part of many pharmaceutical company portfolios. However, the development process of MAbs for clinical use is quite different than for small-molecule drugs. MAb development programs require careful interdisciplinary evaluations to ensure the pharmacology of both the MAb and the target antigen are well-understood. ...
Monoclonal antibodies (MAbs) have become a substantial part of many pharmaceutical company portfolios. However, the developmen
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Viola M, et al. J Control Release 2018 - Review. PMID 30077735
The convenience of subcutaneous (SC) administration and the increasing interest in monoclonal antibody (mAb)-based therapies for chronic diseases, hint their potential for SC delivery in a near future. ...
The convenience of subcutaneous (SC) administration and the increasing interest in monoclonal antibody (mAb)-based therapies for chro …
Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.
Johnson DE. Int J Mol Sci 2018 - Review. PMID 30469350 Free PMC article.
A major portion of these approvals each year are monoclonal antibodies (mAbs). During development, non-clinical pharmacology and toxicology testing of mAbs differs from that done with chemical entities since these biotherapeutics are derived from a biological source and therefore the animal models must share the same epitopes (targets) as humans to elicit a pharmacological response. Mechanisms of toxicity of mAbs are both pharmacological and non-pharmacological in nature; however, standard in silico predictive toxicological methods used in research and development of chemical entities currently do not apply to these biotherapeutics. ...
A major portion of these approvals each year are monoclonal antibodies (mAbs). During development, non-clinical pharmacolog
[Immune-related adverse events by immune checkpoint inhibitors]
Kadono T. Nihon Rinsho Meneki Gakkai Kaishi 2017 - Review. PMID 28603205 Japanese. Free article.
Recent introduction of immune checkpoint inhibitors represented by anti-PD-1 antibodies such as nivolumab and pembrolizumab, and anti-CTLA-4 antibody such as ipilimumab had a great impact on cancer immunotherapy especially for melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. ...
Recent introduction of immune checkpoint inhibitors represented by anti-PD-1 antibodies such as nivolumab and pembrolizumab, and anti …
Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
Kamath AV. Drug Discov Today Technol 2016 - Review. PMID 27978991 Free article.
Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interdependent pharmacokinetic (PK) and pharmacodynamics (PD) properties. ...
Monoclonal antibodies (mAbs) are an important therapeutic class with complex pharmacology and interdependent pharmacoki
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Gordon KB, et al. Lancet 2018 - Clinical Trial. PMID 30097359
BACKGROUND: Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. ...
BACKGROUND: Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key …
Pharmacological interactions of monoclonal antibodies.
Serra López-Matencio JM, et al. Med Clin (Barc) 2018 - Review. PMID 29269128
The pharmacological interactions of biological agents are not well known. Because biologic agents are not metabolised by cytochrome P450 (CYP) enzymes and do not interact with cell membrane transporters, it is generally perceived that they are free from interactions with small molecule drugs. ...In this review, we will provide an outline of the pharmacokinetics properties and pharmacologic interactions of biological drugs, focusing on monoclonal antibodies, and how these can interact with chemical synthesis molecules. ...
The pharmacological interactions of biological agents are not well known. Because biologic agents are not metabolised by cytochrome P …
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin AD, et al. J Crohns Colitis 2016 - Review. PMID 26896086
Compounds that have been tested included the full monoclonal IgG1 antibodies infliximab and adalimumab, the pegylated anti-TNF F[ab']2 fragment certolizumab, an IgG4 anti-TNF CDP571 with reduced affinity for the Fc receptor, the soluble TNF receptor I onercept, and the TNF receptor II-Fc fusion protein etanercept. ...Collectively the data suggest that only IgG1 monoclonal antibodies have the ability to induce complete clinical, biochemical, and endoscopic remission. ...
Compounds that have been tested included the full monoclonal IgG1 antibodies infliximab and adalimumab, the pegylated anti-TNF …
Status of PCSK9 Monoclonal Antibodies in Australia.
Scherer DJ, et al. Heart Lung Circ 2019 - Review. PMID 31104887
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low dens …
30,948 results
Jump to page
Feedback